A collection of third-party insurance payers has filed a class-action lawsuit seeking $9.9 million from St. Jude Medical and parent company Abbott Laboratories, claiming St. Jude knew about a battery defect in its cardiac defibrillators nearly five years before issuing a recall.

Researchers who surveilled of a handful of “Green Carts” in lower-income regions of New York are suggesting increased access to fresh produce—and the ability to pay for those fruits and vegetables with food stamps—could have a positive effect on overall health in disadvantaged areas.

Recent research from PLOS One estimates half of all stents could be unnecessary. No matter how aware and vigilant cardiologists—and, of course all physicians—are in the face of overtreatment, that single statistic is alarming.

Income for American cardiologists continues to rise, with private physicians closing the gap on their integrated counterparts.

The clot-busting stroke drug Activase, which costs $8,010 for a single dose at a rural hospital in Arkansas, is sold to a nearby regional hospital at an 80 percent discount.

Recent guidelines in the U.S. suggest cholesterol-lowering statins should be prescribed more widely to prevent heart disease and aid diabetics, but most people who are newly recommended for the medication can’t afford it.

Howard Broadman understood his grandson, born with one partially functioning kidney, may eventually need a transplant. Broadman just didn’t know if he’d be alive, or healthy enough, to donate when the time came.

Due to a lack of data, CMS has proposed blending the non-surgical and surgical malpractice factors used in rate setting for cardiology procedures—a possibility met with alarm by interventional cardiologists, who perform riskier procedures and pay higher malpractice premiums than general or non-invasive cardiologists.